Business Development, Doctors and In-Vitro - Clinical Research Informer

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist

Scientist In-Vitro Research Life Science

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 per share amounts).

Vaccination

Vaccination Vaccine Production Sales

Clinical Research Informer

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

Webinars

Stay Connected